Celyad

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T-cell (CAR T) therapies for cancer. We are developing multiple allogeneic and autologous CAR T-cell therapy candidates for cancer patients with hematological malignancies and solid tumors. Our lead allogeneic candidate, CYAD-101, is an NKG2D receptor-based CAR T that incorporates our non-gene edited allogeneic TIM technology for the treatment of refractory metastatic colorectal cancer (mCRC). We are also developing CYAD-211, an allogeneic CAR T candidate based on short hairpin RNA (shRNA), for the treatment of relapsed or refractory multiple myeloma (r/r MM). Our autologous CAR T franchise is evaluating our next-generation NKG2D receptor CAR T candidate, CYAD-02, for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndrome (MDS).